Daniel DeAngelo, MD, PhD, is Director of Clinical and Translational Research in Adult Leukemia and Associate Professor of Medicine at the Dana-Farber Cancer Institute. His clinical and research interests include ALL, AML, CML, MDS and MPNs.
Dr DeAngelo completed his medical training at Albert Einstein College of Medicine in 1993, followed by a residency at Massachusetts General Hospital. He then undertook a Clinical Fellowship at the Brigham and Women’s Hospital, and Dana-Farber Cancer Institute, where he joined the staff in 1999.
His research interests include novel therapies and management strategies, including small molecule inhibitors and CAR T-cell therapy.
Steering Committee member for MRD Focus.